Natsuo Ueda Selected Research

Enzymes

12/2022	Formation of N-acyl-phosphatidylethanolamines by cytosolic phospholipase A2ε in an ex vivo murine model of brain ischemia.
6/2017	Inflammation of peripheral tissues and injury to peripheral nerves induce differing effects in the expression of the calcium-sensitive N-arachydonoylethanolamine-synthesizing enzyme and related molecules in rat primary sensory neurons.
1/2017	An involvement of phospholipase A/acyltransferase family proteins in peroxisome regulation and plasmalogen metabolism.
8/2014	New players in the fatty acyl ethanolamide metabolism.
5/2013	Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways.
9/2012	Generation of N-acylphosphatidylethanolamine by members of the phospholipase A/acyltransferase (PLA/AT) family.
11/2011	Enzymological analysis of the tumor suppressor A-C1 reveals a novel group of phospholipid-metabolizing enzymes.
12/2009	Characterization of the human tumor suppressors TIG3 and HRASLS2 as phospholipid-metabolizing enzymes.
11/2008	Expression and secretion of N-acylethanolamine-hydrolysing acid amidase in human prostate cancer cells.
6/2005	A second N-acylethanolamine hydrolase in mammalian tissues.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Natsuo Ueda Research Topics

Disease

12	Neoplasms (Cancer) 01/2023 - 04/2009
2	Overweight 01/2023 - 01/2008
2	Obesity 01/2023 - 01/2008
2	Inflammation (Inflammations) 06/2017 - 01/2009
2	Prostatic Neoplasms (Prostate Cancer) 12/2016 - 11/2008
1	Autosomal Dominant Optic Atrophy (Dominant Optic Atrophy) 10/2023
1	Insulin Resistance 01/2023
1	Epilepsy (Aura) 01/2023
1	Ischemia 12/2022
1	Brain Ischemia (Cerebral Ischemia) 12/2022
1	Pain (Aches) 06/2017
1	Weight Loss (Weight Reduction) 01/2008
1	Leukemia 06/2005
1	Spinal Cord Injuries (Spinal Cord Injury) 01/2002

Drug/Important Bio-Agent (IBA)

10	EnzymesIBA 12/2022 - 06/2005
8	Phospholipases (Phospholipase)IBA 12/2022 - 09/2012
8	AcyltransferasesIBA 01/2017 - 12/2009
6	Proteins (Proteins, Gene)FDA Link 10/2023 - 04/2009
5	N-acylethanolaminesIBA 12/2022 - 11/2008
5	Phospholipids (Phosphatides)FDA LinkGeneric 01/2017 - 12/2009
5	amidaseIBA 12/2016 - 06/2005
5	AcidsIBA 12/2016 - 06/2005
2	LipidsIBA 01/2023 - 01/2009
2	Phosphatidylethanolamines (Cephalins)IBA 12/2022 - 11/2016
2	N-(4-aminophenethyl)spiroperidol (NAPS)IBA 12/2022 - 11/2016
2	1-dodecylpyridoxal (PLD)IBA 06/2017 - 08/2014
2	palmidrolIBA 05/2013 - 01/2009
1	Dynamins (Dynamin)IBA 10/2023
1	CannabidiolIBA 01/2023
1	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 01/2023
1	CannabinoidsIBA 01/2023
1	Glycerophospholipids (Phosphoglycerides)IBA 12/2022
1	CalciumIBA 06/2017
1	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 06/2017
1	AndrogensIBA 12/2016
1	Phospholipases A1 (Phospholipase A1)IBA 07/2015
1	HydrolasesIBA 08/2014
1	LysophospholipidsIBA 05/2013
1	phosphatidylethanolamineIBA 05/2013
1	lecithin-retinol acyltransferaseIBA 12/2009
1	tazarotene (Tazorac)FDA Link 12/2009
1	1-palmitoylphosphatidylethanolamineIBA 01/2009
1	Messenger RNA (mRNA)IBA 11/2008
1	Biomarkers (Surrogate Marker)IBA 11/2008
1	EndocannabinoidsIBA 01/2008
1	RimonabantIBA 01/2008
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2002
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2002
1	Interleukin-1 (Interleukin 1)IBA 01/2002